These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
459 related articles for article (PubMed ID: 9180855)
1. [Tamoxifen adjuvant delays early breast cancer. Results of a cooperative randomized trial]. Delozier T; Switsers O; Génot JY; Ollivier JM; Héry M; Namer M; Frenay M; Kerbrat P; Julien JP; Naja A; Janvier M; Macé-Lesec'h J Bull Cancer; 1997 Jan; 84(1):25-30. PubMed ID: 9180855 [TBL] [Abstract][Full Text] [Related]
2. Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer. Hillner BE Cancer; 2004 Sep; 101(6):1311-22. PubMed ID: 15368322 [TBL] [Abstract][Full Text] [Related]
3. Postoperative adjuvant chemotherapy followed by adjuvant tamoxifen versus nil for patients with operable breast cancer: a randomised phase III trial of the European Organisation for Research and Treatment of Cancer Breast Group. Morales L; Canney P; Dyczka J; Rutgers E; Coleman R; Cufer T; Welnicka-Jaskiewicz M; Nortier J; Bogaerts J; Therasse P; Paridaens R; ; Eur J Cancer; 2007 Jan; 43(2):331-40. PubMed ID: 17134892 [TBL] [Abstract][Full Text] [Related]
4. Tamoxifen versus control after adjuvant, risk-adapted chemotherapy in postmenopausal, receptor-negative patients with breast cancer: a randomized trial (GABG-IV D-93)--the German Adjuvant Breast Cancer Group. Kaufmann M; Graf E; Jonat W; Eiermann W; Geberth M; Albert US; Gademann G; Conrad B; Stahl K; von Minckwitz G; Schumacher M; J Clin Oncol; 2005 Nov; 23(31):7842-8. PubMed ID: 16258087 [TBL] [Abstract][Full Text] [Related]
6. Randomized trial of tamoxifen alone or combined with fluoxymesterone as adjuvant therapy in postmenopausal women with resected estrogen receptor positive breast cancer. North Central Cancer Treatment Group Trial 89-30-52. Ingle JN; Suman VJ; Mailliard JA; Kugler JW; Krook JE; Michalak JC; Pisansky TM; Wold LE; Donohue JH; Goetz MP; Perez EA Breast Cancer Res Treat; 2006 Jul; 98(2):217-22. PubMed ID: 16538529 [TBL] [Abstract][Full Text] [Related]
7. Twelve-year mortality results of a randomized trial of 2 versus 5 years of adjuvant tamoxifen for postmenopausal early-stage breast carcinoma patients (SITAM 01). Belfiglio M; Valentini M; Pellegrini F; De Berardis G; Franciosi M; Rossi MC; Sacco M; Nicolucci A; Cancer; 2005 Dec; 104(11):2334-9. PubMed ID: 16245354 [TBL] [Abstract][Full Text] [Related]
8. Dissemination of adjuvant multiagent chemotherapy and tamoxifen for breast cancer in the United States using estrogen receptor information: 1975-1999. Mariotto AB; Feuer EJ; Harlan LC; Abrams J J Natl Cancer Inst Monogr; 2006; (36):7-15. PubMed ID: 17032888 [TBL] [Abstract][Full Text] [Related]
9. Risk of early recurrence among postmenopausal women with estrogen receptor-positive early breast cancer treated with adjuvant tamoxifen. Kennecke H; McArthur H; Olivotto IA; Speers C; Bajdik C; Chia SK; Ellard S; Norris B; Hayes M; Barnett J; Gelmon KA Cancer; 2008 Apr; 112(7):1437-44. PubMed ID: 18286526 [TBL] [Abstract][Full Text] [Related]
10. Disease-free survival advantage of weekly epirubicin plus tamoxifen versus tamoxifen alone as adjuvant treatment of operable, node-positive, elderly breast cancer patients: 6-year follow-up results of the French adjuvant study group 08 trial. Fargeot P; Bonneterre J; Roché H; Lortholary A; Campone M; Van Praagh I; Monnier A; Namer M; Schraub S; Barats JC; Guastalla JP; Goudier MJ; Chapelle-Marcillac I J Clin Oncol; 2004 Dec; 22(23):4622-30. PubMed ID: 15505276 [TBL] [Abstract][Full Text] [Related]
11. Randomized trial comparing axillary clearance versus no axillary clearance in older patients with breast cancer: first results of International Breast Cancer Study Group Trial 10-93. ; Rudenstam CM; Zahrieh D; Forbes JF; Crivellari D; Holmberg SB; Rey P; Dent D; Campbell I; Bernhard J; Price KN; Castiglione-Gertsch M; Goldhirsch A; Gelber RD; Coates AS J Clin Oncol; 2006 Jan; 24(3):337-44. PubMed ID: 16344321 [TBL] [Abstract][Full Text] [Related]
12. Postoperative adjuvant therapy with tamoxifen, tegafur plus uracil, or both in women with node-negative breast cancer: a pooled analysis of six randomized controlled trials. Noguchi S; Koyama H; Uchino J; Abe R; Miura S; Sugimachi K; Akazawa K; Abe O J Clin Oncol; 2005 Apr; 23(10):2172-84. PubMed ID: 15800310 [TBL] [Abstract][Full Text] [Related]
13. Prognostic factors of early distant recurrence in hormone receptor-positive, postmenopausal breast cancer patients receiving adjuvant tamoxifen therapy: results of a retrospective analysis. Debled M; MacGrogan G; Brouste V; Mathoulin-Pelissier S; Durand M; Mauriac L Cancer; 2007 Jun; 109(11):2197-204. PubMed ID: 17450590 [TBL] [Abstract][Full Text] [Related]
14. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer. Gasparini G; Barbareschi M; Doglioni C; Palma PD; Mauri FA; Boracchi P; Bevilacqua P; Caffo O; Morelli L; Verderio P Clin Cancer Res; 1995 Feb; 1(2):189-98. PubMed ID: 9815973 [TBL] [Abstract][Full Text] [Related]
15. [Adjuvant endocrine treatment of postmenopausal patients with breast cancer with high risk of recurrence. 5. Results from the DBCG (Danish Breast Cancer Cooperative Group) 77C randomized trial]. Rose C; Andersen JA; Andersen KW; Axelsson CK; Blichert-Toft M; Dombernowsky P; Hansen M; Krag C; Mouridsen HT; Overgaard M Ugeskr Laeger; 1991 Aug; 153(33):2283-7. PubMed ID: 1781047 [TBL] [Abstract][Full Text] [Related]
16. The use of early adjuvant aromatase inhibitor therapy: contributions from the BIG 1-98 letrozole trial. Forbes JF Semin Oncol; 2006 Apr; 33(2 Suppl 7):S2-7. PubMed ID: 16730270 [TBL] [Abstract][Full Text] [Related]
17. Co-expression of estrogen receptor alpha and Apolipoprotein D in node positive operable breast cancer--possible relevance for survival and effects of adjuvant tamoxifen in postmenopausal patients. Søiland H; Skaland I; Varhaug JE; Kørner H; Janssen EA; Gudlaugsson E; Baak JP; Søreide JA Acta Oncol; 2009; 48(4):514-21. PubMed ID: 19107621 [TBL] [Abstract][Full Text] [Related]
18. Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93. ; Colleoni M; Gelber S; Goldhirsch A; Aebi S; Castiglione-Gertsch M; Price KN; Coates AS; Gelber RD J Clin Oncol; 2006 Mar; 24(9):1332-41. PubMed ID: 16505417 [TBL] [Abstract][Full Text] [Related]
19. [A randomized controlled study comparing uracil-tegafur (UFT)+tamoxifen (UFT+TAM therapy) with cyclophosphamide+adriamycin+5-fluorouracil (CAF therapy) for women with stage I , II, or IIIa breast cancer with four or more involved nodes in the adjuvant setting]. Inaji H; Sakai K; Oka T; Ozawa K; Saito Y; Senoo T; Taguchi T; Terasawa T; Nakao K; Mori T; Koyama H; Oshima A Gan To Kagaku Ryoho; 2006 Oct; 33(10):1423-9. PubMed ID: 17033231 [TBL] [Abstract][Full Text] [Related]
20. Long-term follow-up of the randomized Stockholm trial on adjuvant tamoxifen among postmenopausal patients with early stage breast cancer. Rutqvist LE; Johansson H; Acta Oncol; 2007; 46(2):133-45. PubMed ID: 17453361 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]